Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County HCV DAA Prior Auth | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Preferred Specialty Management (PSM) Policy for Hepatitis C Virus (HCV) Direct-Acting Antivirals (DAAs)

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and preferred-product management for HCV direct-acting antivirals covered by Ventura County Health Care Plan. It applies to prescribing providers and requires specified patient eligibility, specialist involvement, clinical severity or transmission-risk criteria, and selection of preferred products by genotype.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyPreferred Specialty Management (PSM) Policy for HCV Direct-Acting Antivirals
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSelect a preferred direct-acting antiviral according to the patient's HCV genotype.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    11DAA products affected
    F2+Fibrosis threshold
    18 yearsMinimum age
    12 years / 35 kgAlternative age/weight

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5Preferred-product groups
    ArchivedPolicy status

    Initial Coverage Requirements

    Initial Therapy Criteria

    Initial criteria required: all of the following must be met, with one qualifying clinical pathway.

    Initial therapy

    • Age or weight requirement

      • The patient is at least 18 years of age.≥ 18 years
      • For Harvoni or Sovaldi plus ribavirin, the patient is at least 12 years of age or weighs at least 35 kg.≥ 12 years or ≥ 35 kg
    • Specialist involvement: The medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease physician, or liver transplant physician.
    • Qualifying clinical pathway

      • Hepatic fibrosis: The patient has documented hepatic fibrosis correlating with Metavir stage F2 or higher, assessed by an invasive or noninvasive method.Metavir stage F2 or higher

        Examples include liver biopsy, APRI, FIB-4, FibroScan, and FibroTest/FibroSURE.

      • Severe extrahepatic manifestations

        • The patient has type 2 or 3 essential mixed cryoglobulinemia with end-organ manifestations, such as vasculitis.
        • The patient has proteinuria, nephrotic syndrome, or membranoproliferative glomerular nephritis.
      • High transmission risk and counseling

        • High-risk transmission criterion

    Eligibility Thresholds

    Minimum age
    Minimum age≥ 18 years
    Applies toInitial therapy with a direct-acting antiviral
    RequirementThe patient must meet the age requirement and the specialist-prescriber requirement
    Harvoni or Sovaldi plus ribavirin threshold
    Applicable medicationsHarvoni or Sovaldi plus ribavirin
    Minimum age≥ 12 years
    Alternative weight thresholdWeight ≥ 35 kg

    Prior Authorization and Product Selection

    Prior Authorization

    Initial Prior Authorization

    Prior authorization requires the patient to meet the applicable age or weight requirement, have a qualifying specialist prescriber or consultant, and satisfy at least one covered clinical pathway. The requested drug must then meet its applicable drug-specific criteria.

    Prior Authorization

    Drug-Specific Secondary Criteria

    After initial criteria are met, apply the individual prior authorization drug guideline for the requested medication.

    Step Therapy

    Genotype-Based Preferred Products

    Select a preferred direct-acting antiviral according to the patient’s HCV genotype. Requests for listed nonpreferred products may be redirected to an applicable preferred product.

    Hepatitis C Direct-Acting Antiviral Therapy

    Hepatitis C virus (HCV) direct-acting antivirals (DAAs) are antiviral therapies used to treat chronic hepatitis C infection. This policy prioritizes treatment for patients with significant hepatic fibrosis, severe extrahepatic manifestations, or elevated risk of HCV transmission when appropriate counseling has been provided. Preferred therapy is selected according to the patient’s HCV genotype.

    Clinical Definitions

    Hepatic fibrosis F2 or higher
    ThresholdMetavir stage F2 or higher
    Invasive assessmentLiver biopsy
    Noninvasive assessmentsAPRI score, FIB-4, FibroScan, or FibroTest/FibroSURE
    Severe extrahepatic manifestation
    Qualifying conditionType 2 or 3 essential mixed cryoglobulinemia
    Required manifestationEnd-organ manifestations
    ExampleVasculitis

    Initial DAA Authorization Logic

    Initial DAA Authorization

    Initial therapy is authorized when all foundational requirements are met and at least one qualifying clinical pathway is satisfied.

    Initial DAA authorization

    • Age or weight requirement

      • The patient is at least 18 years of age.≥ 18 years
      • For Harvoni or Sovaldi plus ribavirin, the patient is at least 12 years of age or weighs at least 35 kg.≥ 12 years or ≥ 35 kg
    • Specialist involvement: The medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease physician, or liver transplant physician.

    Genotype-Specific Preferred Products

    GenotypePreferred productsDirection for specified requests
    1Epclusa; Harvoni; Mavyret; Viekira Pak with or without ribavirin; Viekira XR with or without ribavirin; VoseviRequests for Daklinza, Olysio, Sovaldi, or Zepatier are directed to a preferred product.
    GenotypePreferred products
    2Epclusa; Mavyret; Vosevi
    GenotypePreferred productsDirection for specified requests
    3Epclusa; Mavyret; VoseviRequests for Daklinza and/or Sovaldi are directed to a preferred product.
    GenotypePreferred productsDirection for specified requests
    4Epclusa; Harvoni; Mavyret; Technivie; VoseviRequests for Zepatier are directed to a preferred product.
    GenotypePreferred products
    5 or 6Epclusa; Harvoni; Mavyret; Vosevi
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyPreferred Specialty Management (PSM) Policy for HCV Direct-Acting Antivirals
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSelect a preferred direct-acting antiviral according to the patient's HCV genotype.
    SourceLink
    On This Page
    Initial Coverage RequirementsEligibility ThresholdsPrior Authorization and Product SelectionHepatitis C Direct-Acting Antiviral TherapyClinical DefinitionsInitial DAA Authorization LogicGenotype-Specific Preferred Products
    The patient is on long-term hemodialysis.≥ 3 months
  1. The patient is a healthcare worker whose daily activities put them in contact with blood and/or needles.
  2. The patient has been counseled on ways to decrease transmission of HCV and minimize the risk of reinfection with HCV.
  3. Qualifying hepatic fibrosis
    Required fibrosis stageMetavir stage F2 or higher
    Clinical pathwayOne qualifying pathway for initial therapy
    Documentation requirementThe fibrosis score must be documented by an invasive or noninvasive assessment
    Long-term hemodialysis
    Minimum duration≥ 3 months
    Qualifying conditionLong-term hemodialysis
    Additional requirementThe patient must also be counseled on ways to decrease HCV transmission and minimize the risk of reinfection
  4. Genotype 1: Epclusa, Harvoni, Mavyret, Viekira Pak (with or without ribavirin), Viekira XR (with or without ribavirin), and Vosevi. Requests for Daklinza, Olysio, Sovaldi, or Zepatier may be redirected.
  5. Genotype 2: Epclusa, Mavyret, and Vosevi.
  6. Genotype 3: Epclusa, Mavyret, and Vosevi. Requests for Daklinza and/or Sovaldi may be redirected.
  7. Genotype 4: Epclusa, Harvoni, Mavyret, Technivie, and Vosevi. Requests for Zepatier may be redirected.
  8. Genotype 5 or 6: Epclusa, Harvoni, Mavyret, and Vosevi.
  9. Documentation Required

    Initial Clinical Documentation

    Document the initial clinical requirements supporting the request, including the applicable patient age or weight, specialist involvement, and at least one qualifying HCV pathway.

    • Patient is at least 18 years of age; or, for Harvoni or Sovaldi plus ribavirin, is at least 12 years of age or weighs at least 35 kg.
    • Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease physician, or liver transplant physician.
    • Documented hepatic fibrosis correlating with Metavir stage F2 or higher by liver biopsy or a noninvasive method such as APRI, FIB-4, FibroScan, or FibroTest/FibroSURE; or a qualifying severe extrahepatic manifestation; or the qualifying high-transmission-risk pathway with counseling.
    Documentation Required

    Extrahepatic Manifestation Documentation

    When relying on the extrahepatic-manifestation pathway, document a qualifying condition placing the patient at high risk for severe HCV complications.

    • Type 2 or 3 essential mixed cryoglobulinemia with end-organ manifestations, such as vasculitis.
    • Proteinuria, nephrotic syndrome, or membranoproliferative glomerular nephritis.
    Documentation Required

    Transmission-Risk Documentation

    When relying on the transmission-risk pathway, document the qualifying exposure risk and counseling to reduce transmission and reinfection.

    • Long-term hemodialysis for at least 3 months; or
    • Healthcare-worker duties involving daily contact with blood and/or needles; and
    • Counseling on ways to decrease HCV transmission and minimize the risk of reinfection.
    Denial Risk

    Failure to Meet Initial Criteria

    Authorization may be denied or not authorized when the patient does not satisfy the applicable age or weight requirement, specialist-prescriber or consultation requirement, qualifying clinical pathway, or transmission-risk and counseling requirements.

    Step Therapy

    Nonpreferred Product Selection

    A request for a nonpreferred product may be directed to a preferred product based on HCV genotype, including the genotype-specific redirections identified below.

    • Genotype 1 requests for Daklinza, Olysio, Sovaldi, or Zepatier may be directed to a preferred product.
    • Genotype 3 requests for Daklinza and/or Sovaldi may be directed to a preferred product.
    • Genotype 4 requests for Zepatier may be directed to a preferred product.
  10. Qualifying clinical pathway

    • Hepatic fibrosis: The patient has documented hepatic fibrosis correlating with Metavir stage F2 or higher, assessed by an invasive or noninvasive method.Metavir stage F2 or higher

      Examples include liver biopsy, APRI, FIB-4, FibroScan, and FibroTest/FibroSURE.

    • Severe extrahepatic manifestations

      • The patient has type 2 or 3 essential mixed cryoglobulinemia with end-organ manifestations, such as vasculitis.
      • The patient has proteinuria, nephrotic syndrome, or membranoproliferative glomerular nephritis.
    • High transmission risk and counseling

      • High-risk transmission criterion

        • The patient is on long-term hemodialysis.≥ 3 months
        • The patient is a healthcare worker whose daily activities put them in contact with blood and/or needles.
      • The patient has been counseled on ways to decrease transmission of HCV and minimize the risk of reinfection with HCV.